Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor–Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer
Grant D. Stewart(University of Cambridge), Thomas Powles(Queen Mary University of London), Alexander L. R. Lubbock(Institute of Genetics and Cancer), S. Alan McNeill(Edinburgh Cancer Research), Sarah A. Martin(Queen Mary University of London), Ian M. Overton(Institute of Genetics and Cancer), David J. Harrison(NHS Lothian), Axel Bex(The Royal Free Hospital), Jyoti Nanda(Edinburgh Cancer Research), Alan Mackay(Institute of Cancer Research), Lél Eöry(University of Edinburgh), Daniel M. Berney(Queen Mary University of London), Alexander Laird(Pfizer (United States)), Peter Mullen(University of Southern California), Michael Aitchison(The Royal Free Hospital), Sukaina Rashid(Queen Mary University of London), Marie O’Donnell(Birmingham Women’s and Children’s NHS Foundation Trust), Antony C. P. Riddick(Cambridge University Hospitals NHS Foundation Trust), Fiach C. O’Mahony(Edinburgh Cancer Research)
Cited by 43
Related Papers
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2017|1.3k
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma
|Cancer Cell|2017|1.3k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846